Reference number
1753-H

SPECIALTY QUANTITY LIMIT PROGRAM

GILOTRIF (afatinib)

I. PROGRAM DESCRIPTION

The standard limit is designed to allow a quantity sufficient for the most common uses of the medication. The recommended dosing parameters for all FDA-approved indications fall within the standard limits. Coverage of an additional quantity may be reviewed on a case-by-case basis upon request.

II. COVERED QUANTITIES

Medication	Standard Limit	FDA-recommended dosing
Gilotrif 20 mg tablets	30 per 30 days	Initial dose: 40 mg once daily Dose adjustment for severe renal impairment: 30 mg once daily Page adjustment for adverse reactions: resume treatment when the
Gilotrif 30 mg tablets	30 per 30 days	Dose adjustment for adverse reactions: resume treatment when the adverse reaction fully resolves, returns to baseline, or improves to Grade 1. Reinstitute at a reduced dose (10 mg per day less than the dose at which the adverse reaction occurred) Dose adjustment for drug interactions:
Gilotrif 40 mg tablets	30 per 30 days	 Dose adjustment for drug interactions: P-gp inhibitors: reduce daily dose by 10 mg. Resume the previous dose after discontinuation of the P-gp inhibitor. P-gp inducers: increase daily dose by 10 mg. Resume the previous dose after discontinuation of the P-gp inducer.

III. REFERENCE

1. Gilotrif [package insert]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc.; January 2018.

Specialty Quantity Limit Gilotrif 1753-H P2019

pharmaceutical manufacturers that are not affiliated with CVS Caremark.

@ 2019 CVS Caremark. All rights reserved.



This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains prescription brand name drugs that are trademarks or registered trademarks of